|
|
PolyIC:LC |
|
Vaxjo ID |
239 |
|
Vaccine Adjuvant Name |
PolyIC:LC |
|
Alternative Names |
Hiltonol® (stabilized Poly(I:C)) |
|
Adjuvant VO ID |
VO_0005726
|
|
Description |
PolyIC:LC is a synthetic double-stranded RNA analog stabilized with poly-L-lysine and carboxymethylcellulose. It is a TLR3 and MDA-5 agonist, used to enhance immune responses, especially with protein subunit vaccines like HIV-1 Env |
|
Stage of Development |
Clinical Trial |
|
Host Species for Testing |
Human |
|
Components |
Poly-ICLC, a multi-functional immune modulator for treating cancer |
|
Structure |
Synthetic dsRNA analog of polyinosinic-polycytidylic acid, stabilized by poly-L-lysine and carboxymethylcellulose. |
|
Preparation |
Formulated by stabilizing poly(I:C) with poly-L-lysine and carboxymethylcellulose for improved stability and delivery. |
|
Function |
Activates TLR3 and MDA5, and stimulates immune response. [PMC9927404] |
|
Safety |
Well-tolerated in humans and animals in trials; no major structural effect on HIV-1 Env antigens |
| References |
Panigaj et al., 2023: Panigaj M, Skelly E, Beasock D, Marriott I, Johnson MB, Salotti J, Afonin KA. Therapeutic immunomodulation by rationally designed nucleic acids and nucleic acid nanoparticles. Frontiers in immunology. 2023; 14; 1053550. [PubMed: 36798121].
Ratnapriya et al., 2022: Ratnapriya S, Perez-Greene E, Schifanella L, Herschhorn A. Adjuvant-mediated enhancement of the immune response to HIV vaccines. The FEBS journal. 2022; 289(12); 3317-3334. [PubMed: 33705608].
|
|
